Back to news

Citius Oncology Reports 120% Growth in Fourth-Quarter LYMPHIR Shipments

Investivoq FilingTracker

Citius Oncology (CTOR) reported preliminary, unaudited fiscal fourth-quarter 2026 LYMPHIR unit sales to U.S. wholesalers of 792 units for the three months ended September 30, 2026, up 120% from 360 units in the prior fiscal quarter.

Prescribing centers ordered 950 LYMPHIR vials from wholesalers during the quarter, compared with 926 in the fiscal third quarter. The company said 54 institutions had ordered LYMPHIR as of the release date, versus 44 reported on August 14.

  • Fiscal fourth-quarter wholesaler purchases totaled 792 LYMPHIR units.
  • Institutional vial orders totaled 950, compared with 926 in the prior quarter.
  • Citius Oncology said it was more than halfway toward its goal of formulary placement at 100 priority institutions by calendar year-end.
  • The company expects to report complete fiscal 2026 fourth-quarter and full-year results in December with its Form 10-K filing.
  • LYMPHIR was launched in the United States in December 2025 for adults with relapsed or refractory Stage I–III CTCL after at least one prior systemic therapy.
Investivoq Alerts
Receive CTOR Data Alerts
Get market-moving data, filings, and signals for CTOR in real time.
Sign Up

$CTOR Hedge Fund Activity

We have seen 7 institutional investors add shares of $CTOR stock to their portfolio, and 5 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

  • ARMISTICE CAPITAL, LLC removed 483,266 shares (-5.3%) from their portfolio in Q2 2026, for an estimated $314,171
  • UBS GROUP AG added 297,779 shares (+808.3%) to their portfolio in Q2 2026, for an estimated $193,586
  • BLACKROCK, INC. removed 47,454 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $30,849
  • VIRTU FINANCIAL LLC added 21,877 shares (+inf%) to their portfolio in Q2 2026, for an estimated $14,222
  • XTX TOPCO LTD added 20,638 shares (+inf%) to their portfolio in Q2 2026, for an estimated $13,416
  • GEODE CAPITAL MANAGEMENT, LLC removed 19,326 shares (-7.3%) from their portfolio in Q2 2026, for an estimated $12,563
  • TOWER RESEARCH CAPITAL LLC (TRC) added 13,816 shares (+inf%) to their portfolio in Q2 2026, for an estimated $8,981

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.